16th IBD Intensive Advanced Course

16th IBD Intensive Advanced Course
Date
Feb 14-15, 2018
Time 
Feb 14, 2018: 08:45-16:45
Feb 15, 2018: 07:45-12:00
Organisation
EduCom
Target audience 
Junior gastroenterologists
Registration
Upon invitation only - Application deadline: September 8, 2017
ECCO Membership
Regular/Y-ECCO Membership 2018 - register/renew now!
Registration fee
n.a.
Please contact the ECCO Office in case of questions at This email address is being protected from spambots. You need JavaScript enabled to view it.
Acknowledgement
The 16th IBD Intensive Advanced Course is supported by industry


16th IBD Intensive Advanced Course
(as of December 2017)

  • 08:45-09:00 Arrival and distribution of voting pads
    09:00–09:10 1: Welcome 
    Julián Panés, Barcelona, Spain
    James Lindsay, London, United Kingdom
    09:10–10:10 Session 1: Pathogenesis
    Lead discussant: James Lindsay, London, United Kingdom
    09:10-09:25 2: Exposome circled information source
    Jonas Halfvarson, Örebrö, Sweden
    09:25-09:40 3: Genetics circled information source
    Miles Parkes, Cambridge, United Kingdom
    09:40-09:55 4: Inflammatory pathways circled information source
    Yehuda Chowers, Haifa, Israel
      09:55-10:05 Discussion / Questions
    10:05-10:20 Coffee break
    10:20-11:35 Session 2: Drug management session. Part I: Conventional drugs
    Lead discussant: Antonio López-Sanromán, Madrid, Spain
    10:20-10:40 5: 5-ASA compoundscircled information source
    Gerhard Rogler, Zurich, Switzerland

    10:40-11:00 6: Thiopurinescircled information source
    Peter Irving, London, United Kingdom

      11:00-11:15 7: Methotrexatecircled information source
    Pascale Juillerat, Bern, Switzerland

    11:15-11:35 8: Steroidscircled information source
    Stephan Vavricka, Zurich, Switzerland

    11:35-12:55 Session 2: Drug management session. Part II: Biologics
    Lead discussant: Séverine Vermeire, Leuven, Belgium
    11:35-11:55 9: Anti-TNF agentscircled information source
    Filip Baert, Roeselare, Belgium

    11:55-12:10 10: Vedolizumabcircled information source
    James Lindsay, London, United Kingdom

    12:10-12:25 11: Ustekinumabcircled information source
    Marc Ferrante, Leuven, Belgium

      12:25-12:40 12: Tofacitinibcircled information source
    Séverine Vermeire, Leuven, Belgium
      12:40-12:55 Discussion / Question
    12:55–13:30 Lunch break
    13:30-15:00 Session 3: Seminars. Part I: Special clinical situations
    13:30-14:15 EITHER:
    13a: Managing IBD and pregnancycircled information source

    Janneke van der Woude, Rotterdam, The Netherlands
    Iris Dotan, Tel Aviv, Israel
    OR:
    13b: Managing extraintestinal manifestations of IBDcircled information source

    Stephan Vavricka, Zurich, Switzerland
    Peter Lakatos, Budapest, Hungary; Montreal, Canada
    14:15-15:00 EITHER:
    14a: Managing IBD and pregnancycircled information source

    Janneke van der Woude, Rotterdam, The Netherlands
    Iris Dotan, Tel Aviv, Israel

    OR:
    14b: Managing extraintestinal manifestations of IBDcircled information source

    Stephan Vavricka, Zurich, Switzerland
    Peter Lakatos, Budapest, Hungary; Montreal, Canada
    15:00–15:15  Coffee break
    15:15–16:45 Session 3: Seminars. Part II: Long term management
    15:15-16:00 EITHER:
    15a: Managing complications associated with anti-TNF therapycircled information source

    Shomron Ben-Horin, Ramat Gan, Israel
    Axel Dignass, Frankfurt, Germany
    OR: 
    15b: Perform endoscopy and IBD incl. chromo-endoscopy, balloon dilationcircled information source

    Pierre Michetti, Lausanne, Switzerland
    Marc Ferrante, Leuven, Belgium
     16:00-16:45 EITHER:
    16a: Managing complications associated with anti-TNF therapycircled information source
    Shomron Ben-Horin, Ramat Gan, Israel
    Axel Dignass, Frankfurt am Main, Germany
    OR: 
    16b: Perform endoscopy and IBD incl. chromo-endoscopy, balloon dillationcircled information source

    Pierre Michetti, Lausanne, Switzerland
    Marc Ferrante, Leuven, Belgium
  • 07:45-09:25 Session 4: Interactive case discussions
    Lead discussant: Ailsa Hart, London, United Kingdom
    07:45-08:30 17: Case-based discussion: Fistulising Crohn's Disease:  Medical and surgical approachescircled information source
    Case presentation: Antonio López-Sanromán, Madrid, Spain
    Discussion: Paulo Kotze, Curitiba, Brazil; Calgary, Canada

    08:30-08:35 Discussion 
    08:35–09:20 18: Case-based discussion: Optimal management of patient with Severe Crohn's Disease treated with anti-TNF agentscircled information source
    Case presentation: Michael Fitzpatrick, Oxford, United Kingdom
    Discussion: Simon Travis, Oxford, United Kingdom
    09:20-09:25 Discussion/Questions
    09:25-09:45 Coffee break
    09:45-11:50 Session 5: Special cases scenarios
    Lead discussant: Gerassimos Mantzaris, Athens, Greece
    09:45–10:15 19: Medical management of acute severe ulcerative colitiscircled information source
    Corey Siegel, Lebanon, United States
    10:15-10:45 20: Management of refractory pouchitiscircled information source
    Iris Dotan, Petah Tikva, Israel
    10:45-11:15 21: Pre- and postoperative management of Crohn's Diseasecircled information source  
    Glen Doherty, Dublin, Israel
    11:15-11:50 22: Case based discussion: Investigation and management of mild/moderate Crohn's Diseasecircled information source
    Case presentation: Timothy Raine, Cambridge, United Kingdom
    Discussion: Laurence Egan, Galway, Ireland

    11:50-12:00 Feedback and closing remarks
    Pascal Juillerat, Bern, Switzerland